Skip to content
LATEST
Markets

Regulators Mandate Price Reductions for 543 Cancer Drug Brands

Regulators have mandated price cuts for 543 cancer drug brands effective November 9, following a policy to cap trade margins at 30% to improve treatment…

Regulators Mandate Price Reductions for 543 Cancer Drug Brands

National pharmaceutical regulators have mandated significant price reductions for 543 brands of anti-cancer medications, effective November 9. The policy adjustment follows a government decision to cap trade margins at 30% for 137 non-scheduled anti-cancer drugs, aiming to standardize profit margins and improve patient access to essential treatments.

Market data indicates substantial price decreases across various therapeutic categories, with some medications seeing reductions of up to 90%. Notable adjustments include significant drops in the maximum retail price for injections and tablets used in treating breast, colon, and blood-related cancers.

Industry analysts note that while the policy is intended to lower the financial burden on patients, there are concerns regarding the long-term manufacturing viability of low-cost, life-saving drugs. Regulators maintain that the measure is necessary to curb excessive trade margins and ensure the affordability of critical oncology treatments.

More stories

Latest news